Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | IL2 | P60568 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657911 | 0.85 | LTB4R (0.38) | AURKAAURKBLTB4RHPGDKDM4E | |
| SCHEMBL6010423 | 0.78 | LTB4R (0.38) | AURKAAURKBLTB4RNR1I3RORC | |
| SCHEMBL6009561 | 0.75 | FNTA (0.49) | — | |
| SCHEMBL5545656 | 0.75 | LTB4R (0.38) | AURKAAURKBLTB4RNR1I3RORC | |
| SCHEMBL8491691 | 0.70 | HPGD (0.55) | HPGDKDM4EBACE1LMNAMAPT | |
| SCHEMBL25652640 | 0.69 | PTGS2 (0.35) | AURKAAURKBLTB4RRORC | |
| SCHEMBL1757872 | 0.69 | MEN1 (0.49) | AURKAAURKBLTB4RKDM4ENR1I3 | |
| SCHEMBL25652623 | 0.68 | PTGS2 (0.37) | LTB4RMAPT | |
| SCHEMBL6250439 | 0.67 | BRD4 (0.42) | KDM4ELMNAMAPTHTT | |
| SCHEMBL7147632 | 0.67 | LTB4R (0.38) | AURKAAURKBLTB4RNR1I3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173040-B2 | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | JANSSEN-CILAG S.A. (FR) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048882-A1 | Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties | FNTB, FNTA, CYP7A1 | AURKA 1783/4885AURKB 1415/4885LTB4R 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.